Founded on research by Tor Ny, Professor Emeritus of Medical Biochemistry at Umeå University and the founder of Umeå Biotech Incubator, Omnio is developing a plasminogen-based biologic therapy for chronic wounds.
The company’s lead indication is diabetic foot ulcers (DFU), a condition in which wounds can be difficult to heal, with limited effective treatment options.
More than half a billion people worldwide live with diabetes, and up to one-third will develop a foot ulcer during their lifetime. These wounds can become chronic and devastating — severely impacting mobility, quality of life and productivity, while putting patients at risk of amputation.
For healthcare systems, the burden is equally significant, with advanced-stage diabetic foot ulcers costing an estimated €50,000 per wound episode.
“This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies,” says Felipe Velasquez, CEO of Omnio.
Preparing for clinical studies
The company has established its master cell bank and is now scaling up manufacturing in preparation for a GMP batch that will be used in toxicology studies. These studies are required before submitting applications to begin clinical trials. Development has progressed according to plan since the €4.3 million financing round completed in spring 2025.
The clinical study program will begin with a Phase I/IIa safety and early-efficacy study in patients with diabetic foot ulcers.
“Our ambition is to move into patient studies during 2027. We are already evaluating CROs, investigators and trial countries across Europe to support the launch of the clinical program,” says Velasquez.
Addressing a major unmet need in chronic wounds
While diabetic foot ulcers remain the company’s primary focus, Omnio sees broader potential for its plasminogen platform across multiple chronic wound indications in multi-billion-euro markets like venous leg ulcers (VLU), burns, tympanic membrane perforations, infection and periodontitis.
“The wound healing market is mostly a medical devices market, but nothing has really moved the needle in hard-to-heal wounds,” said Velasquez. “We are not developing another medical device. We are developing a biologic therapy that addresses the biology of wound healing and the root cause of why these wounds stay open.”
Headquartered in Umeå, Sweden, Omnio’s R&D operations and scientific team continue to drive the advancement of the company’s plasminogen platform, while clinical operations and quality functions are coordinated from Copenhagen and Barcelona.
Planning the next financing round
Omnio plans to open its next financing round in Q1 2027 to fund clinical development through first efficacy data.
“We are structuring the next financing round around key development milestones as we prepare to enter clinical studies,” says Felipe Velasquez.
About Omnio AB
• Omnio is a Swedish biotechnology company, based in Umeå, developing plasminogen-based therapies for chronic wounds and related conditions.
• Founded on research by Professor Tor Ny at Umeå University (also Head of R&D at Omnio), the company is advancing a biologic treatment designed to address the underlying biology of impaired wound healing.
• The lead indication is diabetic foot ulcers, with potential applications across a broader range of chronic wound conditions.
For more info, contact:
Felipe Velasquez, CEO, Omnio AB
Email: felipe.velasquez@omnio.se
About this announcement
This news is published by Umeå Biotech Incubator (UBI) to highlight developments within Umeå’s life science ecosystem. Omnio AB is an independent company located within UBI’s facilities.